Fennec Pharmaceuticals Inc. Common Stock (FENC) Stock Price

FENCStock

$12.27+38.33%52W

Market Cap$430.27M

P/E—

PEG Ratio1.47

Div yield—

Beta1.22

FENC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)25.78%

Price vs S&P 500 (4W)26.40%

PEG Ratio1.47

VGM Score63.28

P/CF (Annual)8.12x

Book Value / Share (Quarterly)$1.09

P/TBV (Annual)5.91x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)207.19%

Cash Flow / Share (Quarterly)$-0.17

Price vs S&P 500 (YTD)46.53%

Gross Margin (TTM)92.76%

Net Profit Margin (TTM)-12.63%

EPS (TTM)$-0.28

10-Day Avg Trading Volume0.23M

EPS Excl Extra (TTM)$-0.28

Revenue Growth (5Y)204.69%

EPS (Annual)$-0.34

ROI (Annual)-27.46%

Gross Margin (Annual)91.57%

Net Profit Margin (5Y Avg)-2458.16%

Cash / Share (Quarterly)$1.16

Revenue Growth QoQ (YoY)72.64%

ROA (Last FY)-13.81%

Revenue Growth TTM (YoY)33.76%

EBITD / Share (TTM)$-0.25

ROE (5Y Avg)-70.75%

Operating Margin (TTM)-11.81%

Cash Flow / Share (Annual)$-0.37

P/B Ratio11.16x

P/B Ratio (Quarterly)5.63x

Net Income / Employee (Annual)$-270,600

EV / Revenue (TTM)9.19x

Net Interest Coverage (TTM)-6.24x

ROA (TTM)-14.17%

EV / EBITDA (TTM)134.51x

EPS Incl Extra (Annual)$-0.34

Current Ratio (Annual)6.37x

Quick Ratio (Quarterly)6.42x

3-Month Avg Trading Volume0.25M

52-Week Price Return38.33%

EV / Free Cash Flow (Annual)7.99x

Revenue / Employee (TTM)$1,148,500

Tangible BV / Share (Quarterly)$1.39

P/S Ratio (Annual)9.42x

Asset Turnover (Annual)0.63x

52-Week High$13.25

Operating Margin (5Y Avg)-2412.74%

EPS Excl Extra (Annual)$-0.34

26-Week Price Return37.71%

Quick Ratio (Annual)5.87x

13-Week Price Return24.06%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.98x

Enterprise Value$380.14M

Revenue / Share Growth (5Y)193.28%

Asset Turnover (TTM)0.65x

Book Value / Share Growth (5Y)-6.51%

Revenue / Employee (Annual)$1,240,100

Inventory Turnover (Annual)2.87x

Pretax Margin (Annual)-21.58%

Cash / Share (Annual)$1.08

3-Month Return Std Dev62.08%

Net Income / Employee (TTM)$-232,700

ROE (Last FY)-27.46%

Net Interest Coverage (Annual)-6.24x

EPS Basic Excl Extra (Annual)$-0.34

Receivables Turnover (TTM)2.42x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.28

Receivables Turnover (Annual)2.47x

ROI (TTM)-12.54%

P/S Ratio (TTM)10.17x

Pretax Margin (5Y Avg)-2457.96%

Revenue / Share (Annual)$1.56

Tangible BV / Share (Annual)$7.48

Forward P/E18.27x

Price vs S&P 500 (52W)19.77%

Year-to-Date Return59.35%

5-Day Price Return7.63%

EPS Normalized (Annual)$-0.34

ROA (5Y Avg)-47.99%

Net Profit Margin (Annual)-21.82%

Month-to-Date Return28.21%

Cash Flow / Share (TTM)$-0.53

EBITD / Share (Annual)$-0.29

Operating Margin (Annual)-18.60%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-65.46%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.28

P/TBV (Quarterly)15.62x

P/B Ratio (Annual)7.41x

Inventory Turnover (TTM)2.43x

Pretax Margin (TTM)-12.38%

Book Value / Share (Annual)$1.04

Price vs S&P 500 (13W)22.11%

Beta1.22x

P/FCF (Annual)15.58x

Revenue / Share (TTM)$1.16

ROE (TTM)-12.54%

52-Week Low$5.65

vGradeD

gGradeA

mGradeB

vgmGradeB

FENC Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 11, 2026	$0.02	$0.05	+127.27%(+$0.03)
Q1 2026	May 14, 2026	-$0.02	$0.01	+159.99%(+$0.03)
Q4 2025	Mar 24, 2026	$0.04	-$0.10	-350.25%(-$0.14)
Q3 2025	Nov 13, 2025	-$0.02	-$0.02	+9.09%(+$0.00)
Q2 2025	Aug 14, 2025	-$0.03	-$0.11	-266.67%(-$0.08)

FENC Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.23

4.17

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
FENCFennec Pharmaceuticals Inc. Common Stock	D	A	B	$12.27
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93

About Fennec Pharmaceuticals Inc. Common Stock

Fennec Pharmaceuticals is a biopharmaceutical company commercializing PEDMARK, a novel formulation designed to prevent cisplatin-induced hearing loss in children undergoing chemotherapy. The company addresses a significant side effect of cancer treatment with a first-in-class therapeutic approach. Operations are based in the United States.